CA2884521C - Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence - Google Patents

Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence Download PDF

Info

Publication number
CA2884521C
CA2884521C CA2884521A CA2884521A CA2884521C CA 2884521 C CA2884521 C CA 2884521C CA 2884521 A CA2884521 A CA 2884521A CA 2884521 A CA2884521 A CA 2884521A CA 2884521 C CA2884521 C CA 2884521C
Authority
CA
Canada
Prior art keywords
hemoglobin
cells
tumor
cancer
oxygen carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2884521A
Other languages
English (en)
French (fr)
Other versions
CA2884521A1 (en
Inventor
Bing Lou Wong
Norman Fung Man Wai
Sui Yi Kwok
Sze Hang Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VISION GLOBAL HOLDINGS Ltd
Original Assignee
VISION GLOBAL HOLDINGS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VISION GLOBAL HOLDINGS Ltd filed Critical VISION GLOBAL HOLDINGS Ltd
Publication of CA2884521A1 publication Critical patent/CA2884521A1/en
Application granted granted Critical
Publication of CA2884521C publication Critical patent/CA2884521C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2884521A 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence Active CA2884521C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US61/712,853 2012-10-12
US13/713,031 2012-12-13
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
PCT/US2013/064418 WO2014059199A1 (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (2)

Publication Number Publication Date
CA2884521A1 CA2884521A1 (en) 2014-04-17
CA2884521C true CA2884521C (en) 2018-05-01

Family

ID=50475529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2884521A Active CA2884521C (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Country Status (21)

Country Link
US (2) US20140106004A1 (https=)
EP (1) EP2906222A4 (https=)
JP (1) JP6113850B2 (https=)
KR (1) KR20150065881A (https=)
CN (1) CN104717966B (https=)
AP (1) AP2015008315A0 (https=)
AR (1) AR093023A1 (https=)
AU (1) AU2013329121B2 (https=)
BR (1) BR112015007475A2 (https=)
CA (1) CA2884521C (https=)
CL (1) CL2015000897A1 (https=)
EA (1) EA201500301A1 (https=)
IL (1) IL237763A (https=)
MA (1) MA37994A2 (https=)
MX (1) MX367562B (https=)
PH (1) PH12015500562B1 (https=)
SG (3) SG10201608747RA (https=)
TW (1) TW201414489A (https=)
UY (1) UY35082A (https=)
WO (1) WO2014059199A1 (https=)
ZA (1) ZA201501949B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
KR102854338B1 (ko) 2017-06-26 2025-09-03 루넬라 바이오테크 인코포레이티드 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제
JPWO2019124423A1 (ja) * 2017-12-19 2020-10-22 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び／又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
KR102793996B1 (ko) 2022-03-31 2025-04-09 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119746044A (zh) * 2025-03-06 2025-04-04 润方（北京）生物医药研究院有限公司 血红蛋白氧载体在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
NO2440239T3 (https=) * 2009-06-09 2018-02-10
EP2451459B1 (en) * 2009-07-07 2017-11-22 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
JP2015534946A (ja) 2015-12-07
AU2013329121A1 (en) 2015-04-09
PH12015500562A1 (en) 2015-05-04
US9056098B2 (en) 2015-06-16
ZA201501949B (en) 2016-01-27
SG11201502133SA (en) 2015-04-29
BR112015007475A2 (pt) 2017-08-08
US20140106004A1 (en) 2014-04-17
SG10201608747RA (en) 2016-12-29
JP6113850B2 (ja) 2017-04-12
WO2014059199A8 (en) 2014-05-30
IL237763A (en) 2017-07-31
CN104717966A (zh) 2015-06-17
MX2015004512A (es) 2015-12-01
EA201500301A1 (ru) 2015-08-31
EP2906222A4 (en) 2016-06-22
MX367562B (es) 2019-08-27
PH12015500562B1 (en) 2015-05-04
TW201414489A (zh) 2014-04-16
HK1206281A1 (en) 2016-01-08
EP2906222A1 (en) 2015-08-19
SG10201607846PA (en) 2016-11-29
CA2884521A1 (en) 2014-04-17
US20140303085A1 (en) 2014-10-09
CL2015000897A1 (es) 2015-08-21
UY35082A (es) 2014-07-31
MA37994A2 (fr) 2016-06-30
AR093023A1 (es) 2015-05-13
AU2013329121B2 (en) 2017-05-25
AP2015008315A0 (en) 2015-03-31
CN104717966B (zh) 2018-08-24
KR20150065881A (ko) 2015-06-15
WO2014059199A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CA2884521C (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
Luo et al. Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose
Secchiero et al. Recent advances in the therapeutic perspectives of Nutlin-3
Gao et al. Mitochondrion-targeted supramolecular “nano-boat” simultaneously inhibiting dual energy metabolism for tumor selective and synergistic chemo-radiotherapy
Jin et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo
WO2014186301A1 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
Gao et al. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes
CN114099542B (zh) 普鲁士蓝及其类似物在制备预防、延缓或治疗与程序性细胞坏死相关疾病药物中的应用
JPWO2018021200A1 (ja) Ｒｕｎｘ阻害剤
Feng et al. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity: J. Feng, Y. Wu
JP6527825B2 (ja) 癌を処置するための環形動物のヘモグロビンの使用
Wang et al. Engineered microparticles modulate arginine metabolism to repolarize tumor-associated macrophages for refractory colorectal cancer treatment
Lee et al. Feedback amplification of senolysis using caspase-3-cleavable peptide-doxorubicin conjugate and 2DG
JP2018035112A (ja) 抗癌剤の抗腫瘍効果の増強剤、癌治療剤、及び癌治療用医薬組成物。
Luke et al. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors
El-Sisi et al. Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice
Shia et al. Preclinical pharmacokinetic, pharmacodynamic, and safety profile of OBI-992: a novel TROP2-targeted antibody–drug conjugate
JP6861162B2 (ja) アポエクオリン含有組成物および神経細胞の炎症を治療するためのアポエクオリンの使用方法
Kang et al. Dual inhibitors of P-glycoprotein and breast cancer resistance protein for overcoming the blood–brain barrier: in silico discovery and preclinical evaluation
HK1206281B (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
Li et al. An albumin-prodrug injectable formulation for synergistic cancer immunotherapy
KR20200067785A (ko) 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
US10550130B2 (en) Benzo-thiazolo-imidazole compounds and uses thereof
KR102119197B1 (ko) 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
US20180230466A1 (en) Methods for treating tumors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251125

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260114